Forester Capital Management’s AstraZeneca AZN Stock Holding History

Forester Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$109K	Hold	1,600	–	–	0.15%	47
2017 Q1	$100K	Hold	1,600	–	–	0.12%	49
2016 Q4	$87K	Hold	1,600	–	–	0.09%	54
2016 Q3	$105K	Hold	1,600	–	–	0.1%	56
2016 Q2	$97K	Hold	1,600	–	–	0.09%	51
2016 Q1	$109K	Buy	1,600 +650	+68%	+$39.1K	0.1%	54
2015 Q4	$65K	Hold	950	–	–	0.06%	55
2015 Q3	$60K	Sell	950 -950	-50%	-$62.5K	0.06%	55
2015 Q2	$61K	Buy	1,900 +950	+100%	+$65K	0.05%	55
2015 Q1	$65K	Hold	950	–	–	0.05%	56
2014 Q4	$67K	Hold	950	–	–	0.05%	56
2014 Q3	$68K	Hold	950	–	–	0.05%	57
2014 Q2	$71K	Sell	950 -2,500	-72%	-$181K	0.06%	55
2014 Q1	$224K	Sell	3,450 -2,085	-38%	-$135K	0.17%	39
2013 Q4	$329K	Sell	5,535 -950	-15%	-$51.6K	0.26%	31
2013 Q3	$337K	Hold	6,485	–	–	0.27%	37
2013 Q2	$307K	Buy	+6,485	New	+$330K	0.25%	39

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Forester Capital Management's AZN Position: Q2 2017 in Review

Forester Capital Management held its AstraZeneca (AZN) position steady in Q2 2017 at 1,600 shares worth $109K. The position accounts for 0.15% of the portfolio, ranked #47.

Forester Capital Management first reported a position in AZN in Q2 2013 and has held it in 17 quarters since. The position peaked at $337K in Q3 2013. 467 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

Forester Capital Management held 1,600 shares of AstraZeneca worth $109K as of Q2 2017.
Forester Capital Management left its AstraZeneca share count unchanged in Q2 2017.
AstraZeneca made up 0.15% of Forester Capital Management's portfolio in Q2 2017, its #47 holding.
Forester Capital Management first reported a position in AstraZeneca in Q2 2013 and has held it in 17 quarters since.
Forester Capital Management's AstraZeneca position peaked at $337K in Q3 2013.
467 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Forester Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.